Neal W Bost, MD
Diagnostic Radiology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 7
- Since medical school
- 13 years
- Tulane University School of Medicine, 2013
Offices
7 locations · UCSF Medical Group Business Services · University of California San Francisco
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bost’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A131760 · Current
Licensed to practise in California · since 2014 · expires 2028-02-29 · Tulane University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Radiology - Diagnostic Radiology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$787,488
Medicare paid this office $787,488 for 1,750 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Mri scan of pelvis before and after contrast | 682 | $197,495 | $283 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 102 | $152,955 | $1,485 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 17 | $79,353 | $519 |
| Florbetapir f18, diagnostic, per study dose, up to 10 millicuries | 24 | $61,292 | $2,554 |
| Nuclear medicine study limited area with ct scan | 30 | $45,511 | $1,517 |
See all 26 services
| Mri scan of pelvis before and after contrast | 682 | $197,495 | $283 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 102 | $152,955 | $1,485 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 17 | $79,353 | $519 |
| Florbetapir f18, diagnostic, per study dose, up to 10 millicuries | 24 | $61,292 | $2,554 |
| Nuclear medicine study limited area with ct scan | 30 | $45,511 | $1,517 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 103 | $29,998 | $288 |
| Ct scan of chest without contrast | 208 | $22,299 | $107 |
| Ct scan of abdomen and pelvis before and after contrast | 72 | $22,205 | $308 |
| Ct scan of abdomen and pelvis with contrast | 73 | $19,656 | $269 |
| Mri scan of abdomen before and after contrast | 59 | $18,847 | $314 |
| Nuclear medicine study whole body with ct scan | 12 | $18,367 | $1,531 |
| Injection, gadoterate meglumine, 0.1 ml | 694 | $11,805 | $0 |
| Ct scan of abdomen and pelvis without contrast | 57 | $9,194 | $161 |
| Mri scan of pelvis without contrast | 40 | $7,453 | $182 |
| 3d radiographic procedure with computerized image postprocessing | 110 | $7,381 | $65 |
| Ultrasound scan of head and neck soft tissue | 60 | $5,222 | $87 |
| Ct scan of chest with contrast | 48 | $5,173 | $108 |
| Complete ultrasound scan behind abdominal cavity | 32 | $2,865 | $90 |
| Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 11 | $2,692 | $245 |
| Complete ultrasound scan of abdomen | 29 | $2,268 | $78 |
| X-ray of chest, 2 views | 78 | $2,121 | $27 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 175 | $1,672 | $0 |
| Limited ultrasound scan behind abdominal cavity | 31 | $1,587 | $51 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 14 | $777 | $52 |
| 3d radiographic procedure | 27 | $632 | $23 |
| X-ray of abdomen, 1 view | 18 | $495 | $28 |
Who their Medicare patients are
1,750 Original Medicare patients in 2024. Average age 74 · Under 65 4% · 85 and older 8% · Women 36% · Also on Medicaid 17% · Health risk score 1.13. At or below the middle of the specialty; the typical diagnostic radiology clinician is at 1.7.
Conditions among them: High blood pressure 74% · Coronary heart disease 34% · Cancer 34% · Diabetes 30% · Chronic kidney disease 21% · Depression 19% · COPD 17% · Atrial fibrillation 16% · Heart failure 13% · Stroke 8% · Dementia 6%.
The office billed $2,706,208, Medicare allowed $1,008,588 and paid $787,488; for 143,245 services of 105 kinds; $13,940 of it was for drugs given in the office and $773,548 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,750 | 143,245 | 74 | 1.13 | $2,706,208 | $787,488 |
| 2023 | 2,058 | 119,202 | 75 | 1.31 | $3,153,550 | $1,058,111 |
| 2022 | 2,121 | 108,878 | 75 | 1.25 | $2,491,977 | $703,925 |
| 2021 | 1,269 | 50,011 | 73 | 1.71 | $1,768,879 | $585,135 |
| 2020 | 695 | 32,666 | 72 | 1.76 | $1,315,254 | $439,677 |
| 2019 | 112 | 4,945 | 72 | 1.50 | $225,024 | $76,796 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 32 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 219 | $343,125 | $1,485 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 33 | $145,332 | $489 |
| Mri scan of pelvis before and after contrast | 411 | $124,796 | $286 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 209 | $63,878 | $286 |
| Ct scan of abdomen and pelvis with contrast | 146 | $41,885 | $279 |
| Ct scan of abdomen and pelvis before and after contrast | 120 | $39,059 | $323 |
| Nuclear medicine study whole body with ct scan | 23 | $37,119 | $1,485 |
| Ct scan of chest without contrast | 256 | $30,031 | $116 |
| 3d radiographic procedure with computerized image postprocessing | 384 | $25,812 | $63 |
| Ct scan of abdomen and pelvis without contrast | 141 | $23,413 | $165 |
| Mri scan of abdomen before and after contrast | 60 | $19,982 | $322 |
| Ct scan of chest with contrast | 114 | $12,863 | $108 |
| Ultrasound scan of head and neck soft tissue | 120 | $11,337 | $94 |
| Injection, gadoterate meglumine, 0.1 ml | 455 | $9,337 | $0 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 22 | $8,892 | $404 |
| Nuclear medicine study of bone and/or joint whole body | 26 | $6,662 | $247 |
| Ct scan of abdomen before and after contrast | 25 | $5,683 | $227 |
| Complete ultrasound scan behind abdominal cavity | 62 | $5,639 | $91 |
| Mri scan of pelvis without contrast | 21 | $4,520 | $205 |
| Complete ultrasound scan of abdomen | 44 | $4,164 | $95 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 343 | $3,894 | $0 |
| Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 14 | $3,420 | $244 |
| X-ray of chest, 2 views | 112 | $3,320 | $29 |
| Mri scan of abdomen without contrast | 16 | $2,586 | $162 |
| Limited ultrasound scan behind abdominal cavity | 40 | $1,860 | $46 |
| Double contrast x-ray of esophagus | 16 | $1,361 | $85 |
| Limited ultrasound scan of abdomen | 19 | $1,209 | $64 |
| X-ray of abdomen, 1 view | 40 | $1,004 | $25 |
| X-ray of ribs on side of body, minimum of 3 views | 22 | $788 | $36 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 18 | $660 | $33 |
| 3d radiographic procedure | 23 | $506 | $22 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 29 | $357 | $12 |
2022: 31 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 115 | $180,613 | $1,505 |
| Mri scan of pelvis before and after contrast | 318 | $101,121 | $299 |
| Ct scan of abdomen and pelvis before and after contrast | 222 | $74,409 | $332 |
| Ct scan of chest without contrast | 338 | $41,239 | $118 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 126 | $38,332 | $288 |
| Nuclear medicine study whole body with ct scan | 18 | $28,470 | $1,498 |
| Mri scan of abdomen before and after contrast | 83 | $27,139 | $323 |
| Ct scan of abdomen and pelvis without contrast | 152 | $26,028 | $170 |
| Ct scan of abdomen and pelvis with contrast | 73 | $21,966 | $297 |
| 3d radiographic procedure with computerized image postprocessing | 292 | $19,012 | $61 |
| Ct scan of chest with contrast | 129 | $15,019 | $111 |
| Ultrasound scan of head and neck soft tissue | 119 | $11,882 | $98 |
| Injection, gadoterate meglumine, 0.1 ml | 388 | $8,147 | $0 |
| Complete ultrasound scan behind abdominal cavity | 71 | $7,175 | $100 |
| Mri scan of pelvis without contrast | 30 | $6,672 | $222 |
| X-ray of chest, 2 views | 193 | $5,484 | $28 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $4,732 | $430 |
| Complete ultrasound scan of abdomen | 43 | $4,115 | $96 |
| Ct scan of abdomen before and after contrast | 16 | $3,205 | $200 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 381 | $3,197 | $0 |
| Ct scan of pelvis without contrast | 26 | $2,881 | $107 |
| Ct scan of chest before and after contrast | 18 | $2,368 | $132 |
| Mri scan of abdomen without contrast | 11 | $2,063 | $188 |
| Double contrast x-ray of esophagus | 22 | $2,057 | $94 |
| X-ray of abdomen, 1 view | 76 | $2,008 | $26 |
| Limited ultrasound scan behind abdominal cavity | 42 | $1,935 | $46 |
| Limited ultrasound scan of abdomen | 25 | $1,800 | $72 |
| Ct scan of abdomen without contrast | 14 | $1,751 | $125 |
| Complete x-ray of body bones | 14 | $1,321 | $94 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 26 | $1,306 | $48 |
| X-ray of ribs on side of body, minimum of 3 views | 33 | $1,153 | $34 |
2021: 36 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 170 | $275,752 | $1,352 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 190 | $59,730 | $262 |
| Mri scan of pelvis before and after contrast | 128 | $40,735 | $311 |
| Ct scan of abdomen and pelvis before and after contrast | 110 | $34,858 | $317 |
| Nuclear medicine study whole body with ct scan | 23 | $34,176 | $1,367 |
| Mri scan of abdomen before and after contrast | 45 | $15,334 | $333 |
| Ct scan of abdomen and pelvis without contrast | 70 | $11,301 | $161 |
| Ct scan of chest without contrast | 83 | $10,144 | $121 |
| Ct scan of abdomen and pelvis with contrast | 24 | $6,873 | $286 |
| Ct scan of chest with contrast | 45 | $5,452 | $121 |
| Injection, gadoterate meglumine, 0.1 ml | 163 | $3,886 | $0 |
| 3d radiographic procedure with computerized image postprocessing | 57 | $3,587 | $63 |
| Ct scan of chest before and after contrast | 23 | $3,484 | $139 |
| Mri scan of pelvis without contrast | 12 | $2,708 | $226 |
| Ct scan of blood vessels of chest with contrast | 12 | $2,708 | $226 |
| Ct scan of abdomen before and after contrast | 13 | $2,541 | $195 |
| Mri scan of abdomen without contrast | 13 | $2,488 | $191 |
| Ct scan head or brain without contrast | 75 | $2,170 | $28 |
| Ct scan of abdomen and pelvis with contrast | 30 | $2,068 | $69 |
| Ct scan of abdomen and pelvis without contrast | 28 | $1,927 | $69 |
| Ultrasound scan of head and neck soft tissue | 18 | $1,798 | $100 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 198 | $1,769 | $0 |
| Complete ultrasound scan of abdomen | 14 | $1,588 | $113 |
| Complete ultrasound scan behind abdominal cavity | 14 | $1,468 | $105 |
| Limited ultrasound scan behind abdominal cavity | 20 | $1,063 | $53 |
| X-ray of chest, 1 view | 142 | $1,002 | $7 |
| Ct scan of blood vessels of chest with contrast | 12 | $810 | $68 |
| X-ray of abdomen, 1 view | 26 | $688 | $25 |
| X-ray of chest, 2 views | 24 | $604 | $25 |
| Ct scan of chest with contrast | 13 | $598 | $46 |
| Ct scan of chest without contrast | 17 | $532 | $31 |
| Ct scan of upper spine without contrast | 12 | $442 | $37 |
| X-ray of ribs on side of body, minimum of 3 views | 13 | $417 | $32 |
| Limited ultrasound scan behind abdominal cavity | 11 | $257 | $23 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 14 | $215 | $15 |
| X-ray of chest, 2 views | 17 | $143 | $8 |
2020: 14 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 151 | $245,309 | $1,298 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 170 | $41,197 | $197 |
| Nuclear medicine study whole body with ct scan | 20 | $29,025 | $1,319 |
| Mri scan of pelvis before and after contrast | 86 | $28,995 | $322 |
| Ct scan of abdomen and pelvis before and after contrast | 65 | $19,920 | $306 |
| Ct scan of chest without contrast | 73 | $9,558 | $131 |
| Ct scan of abdomen and pelvis without contrast | 53 | $8,719 | $161 |
| Ct scan of abdomen and pelvis with contrast | 24 | $6,474 | $270 |
| Ct scan of chest with contrast | 29 | $4,221 | $146 |
| Injection, gadoterate meglumine, 0.1 ml | 94 | $2,727 | $0 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 146 | $1,113 | $0 |
| X-ray of chest, 2 views | 20 | $488 | $24 |
| Ct scan head or brain without contrast | 13 | $414 | $32 |
| X-ray of chest, 1 view | 31 | $262 | $8 |
2019: 6 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 35 | $43,941 | $1,255 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 42 | $8,232 | $196 |
| Mri scan of pelvis before and after contrast | 13 | $4,187 | $322 |
| Ct scan of chest without contrast | 18 | $2,301 | $128 |
| Injection, gadoterate meglumine, 0.1 ml | 17 | $462 | $0 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 19 | $149 | $0 |
Medicaid work
$23,293 in 2024
Medicaid paid $23,293 for 216 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences | 59 | $14,807 |
| Unlisted magnetic resonance procedure (eg, diagnostic, interventional) | 66 | $6,464 |
| Radiologic examination, spine, lumbosacral; minimum of 4 views | 16 | $704 |
| Radiologic examination, knee; 3 views | 21 | $504 |
| X-RAY EXAM OF SHOULDER | 16 | $454 |
| Injection, gadoterate meglumine, 0.1 ml | 38 | $360 |
| 2024 | 216 | 6 | 25 | $23,293 |
| 2023 | 25 | 2 | 12 | $2,520 |
| 2021 | 1,839 | 23 | 160 | $308,304 |
| 2020 | 735 | 10 | 49 | $261,711 |
| 2019 | 54 | 2 | 16 | $33,524 |
See the largest Medicaid services in earlier years
2023
| Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences | 13 | $1,624 |
| Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation | 12 | $896 |
2021
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 257 | $245,198 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 142 | $10,085 |
| Computed tomography, abdomen and pelvis; without contrast material in one or both body regions, followed by contrast material(s) and further sections in one or both body regions | 57 | $9,570 |
| CT ABDOMEN & PELVIS W/CONTRAST MATERIAL | 135 | $9,453 |
| CT ABDOMEN & PELVIS W/O CONTRAST MATERIAL | 116 | $9,076 |
| Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences | 16 | $6,008 |
| Computed tomography, head or brain; without contrast material | 175 | $5,546 |
| Computed tomography, thorax, diagnostic; without contrast material | 44 | $2,879 |
| Radiologic examination, chest; single view | 347 | $2,806 |
| Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing | 17 | $1,302 |
| Radiologic examination, chest; 2 views | 137 | $1,281 |
| DIAGNOSTIC COMPUTED TOMOGRAPHY THORAX W/CONTRAST | 19 | $1,278 |
2020
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 210 | $245,663 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 158 | $5,751 |
| Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences | 19 | $4,129 |
| Computed tomography, thorax, diagnostic; without contrast material | 18 | $2,356 |
| CT ABDOMEN & PELVIS W/O CONTRAST MATERIAL | 17 | $1,478 |
| CT ABDOMEN & PELVIS W/CONTRAST MATERIAL | 13 | $1,047 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 86 | $543 |
| Radiologic examination, chest; single view | 65 | $425 |
| Computed tomography, head or brain; without contrast material | 14 | $320 |
| Final reports with documentation of one or more dose reduction techniques (e.g., automated exposure control, adjustment of the ma and/or kv according to patient size, use of iterative reconstruction technique) | 135 | $0 |
2019
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 26 | $32,186 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 28 | $1,338 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 11% of their 108 Part D prescriptions in 2013.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2014 | 187 | 29 | None | 26% | $11,003 |
| 2013 | 108 | 24 | 11% (12) | None | $3,912 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2014: 4 drugs
| Atorvastatin | 28 | $1,046 | $37 |
| Clopidogrel | 16 | $773 | $48 |
| Furosemide | 13 | $152 | $12 |
| Lisinopril | 11 | $128 | $12 |
Money from drug and device companies
$49 in 2022
A payment is not proof that care is biased.
| Progenics Pharmaceuticals | Pylarify | $49 | 1 payment
|
See the published payment
| Progenics Pharmaceuticals | Meals · 2022-09-29 | Pylarify | $49 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 92.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1598101578
- Licence
- CA A131760California A131760: Current · expires 2028-02-29
- Trained
- Tulane University School of Medicine, 2013 · 13 years ago
- Group
- UCSF Medical Group Business Services · University of California San Francisco
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Diagnostic radiology (2085R0202X); Student in a training program (390200000X)
- Mailing address
- 2445 Ranchgrove Dr, Westlake Village, CA, 91361
- NPI first listed
- 2013-05-16
- NPI last updated
- 2025-07-14
- NPI record certified
- 2025-07-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 415 Rolling Oaks Dr Ste 230, Thousand Oaks, CA, 91361